Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance

Adaptive Biotechnologies CorpTrade
Roundhill Magnificent Seven ETFTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Roundhill Magnificent Seven ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Roundhill Magnificent Seven ETF trades at $67.65. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Roundhill Magnificent Seven ETF nearer its low. Which is the better fit depends on your goals.

ADPTMAGS
Market Cap
$4.04B
Sector
HealthSector/Thematic
52-Week High
$25.45$70.94
52-Week Low
$12.30$55.39
Enterprise Value
$4.10B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.

The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.

Roundhill Magnificent Seven ETF

MAGS (Roundhill Magnificent Seven ETF) trades at $67.685, down 1.96% with technical indicators showing bullish moving averages but overbought RSI levels. The ETF faces headwinds as AI spending pressures tech balance sheets, with recent underperformance against the broader market. News sentiment highlights a shift away from concentrated tech exposure toward diversified sectors.

The outlook remains cautious as AI capital expenditures weigh on near-term returns, though long-term AI adoption potential persists. Key risks include tech concentration, valuation compression, and earnings growth sustainability. Investors should monitor broadening market trends and hyperscaler cash flow improvements for catalyst opportunities.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Roundhill Magnificent Seven ETF

MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.

Read more on MAGS